Results 111 to 120 of about 3,619 (165)

Patient perspectives on medications for alcohol use disorder: A systematic scoping review. [PDF]

Alcohol Clin Exp Res (Hoboken)
Tomlinson DC, Florimbio AR, Lee CA, Ilgen MA, Lin LA, Coughlin LN.   +5 more
europepmc   +1 more source

Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans.

JAMA Netw Open
Stewart MT, Feltus SR, Andrews CM, Acevedo A, Thomas CP, Bratberg J, Horgan CM, Hodgkin D, Adams RS.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Acamprosate

Expert Opinion on Drug Metabolism & Toxicology, 2010
Alcohol abuse and dependence are major causes of morbidity and mortality and come with a high societal cost. The illness is notoriously difficult to treat and relapse is a common occurrence. Acamprosate represents an effective addition to the treatment options available for alcohol dependence with a novel mechanism of action.We review the published ...
William Klugh, Kennedy, Megan, Leloux, Eric C, Kutscher, Paul L, Price, Anne E, Morstad, Ryan M, Carnahan   +5 more
openaire   +3 more sources

The clinical pharmacology of acamprosate [PDF]

British Journal of Clinical Pharmacology, 2014
Acamprosate is one of the few medications licensed for prevention of relapse in alcohol dependence, and over time it has proved to be significantly, if moderately, effective, safe and tolerable. Its use is now being extended into other addictions and neurodevelopmental disorders.
Nicola J Kalk
exaly   +3 more sources

Acamprosate

PharmacoEconomics, 1999
Acamprosate is thought to reduce the craving for alcohol. The drug helps to maintain abstinence in alcohol-dependent patients who have successfully undergone detoxification. Abstinence rates during 3 to 12 months' treatment with acamprosate were approximately double those with placebo in most clinical trials, although abstinence rates were generally ...
Rachel H. Foster, Karen J. McClellan
openaire   +3 more sources

Clinical Pharmacokinetics of Acamprosate

Clinical Pharmacokinetics, 1998
Acamprosate is a new psychotropic drug used in the treatment of alcohol (ethanol)-dependence. Recent studies suggest that acamprosate inhibits neuronal hyperexcitability by antagonising excitatory amino acids. It is available as a 333 mg enteric-coated tablet, with a recommended dosage of 1.3 g/day for patients with a bodyweight < 60 kg and 2 g/day for
S, Saivin, T, Hulot, S, Chabac, A, Potgieter, P, Durbin, G, Houin   +5 more
openaire   +2 more sources

Acamprosate and Primitive Reflexes

Annals of Pharmacotherapy, 2007
Objective: To describe 3 cases of patients with alcohol dependence whose primitive reflexes resolved upon initiation of acamprosate 666 mg 3 times daily. Case Summaries: A 57-year-old man had a long-standing history of alcohol ...
Patrycya, Guzik, Lindey, Bankes, Thomas M, Brown   +2 more
openaire   +2 more sources

Treatment of tinnitus with acamprosate

2007
Acamprosate, a drug used to treat alcohol dependence, was first reported as a potential treatment for tinnitus in 2005. The drug may improve tinnitus by a dual mechanism of action, acting both as a glutamate antagonist and as a GABA agonist. It is suggested that its action may be both on the ear and the nervous system.
Andréia Aparecida de, Azevedo, Ricardo Rodrigues, Figueiredo   +1 more
openaire   +2 more sources

Potential Neuroprotective Effects of Acamprosate

Alcoholism: Clinical and Experimental Research, 2002
This article represents the proceedings of a symposium at the 2001 RSA Meeting in Montreal, Canada. The organizers were Barbara J. Mason and George F. Koob. Anita M. Goodman served as chair. The presentations were (1) Acamprosate inhibits alcohol withdrawal‐induced neurotoxicity in organotypic hippocampal cultures, by John Littleton; (2) Acamprosate ...
George F, Koob, Barbara J, Mason, Philippe, De Witte, John, Littleton, George R, Siggins   +4 more
openaire   +2 more sources